MRD at TP1 and TP2, as stratified by genomic risk group
| B-ALL . | MRD at TP1 . | MRD at TP2 . | ||
|---|---|---|---|---|
| . | POS . | NEG . | POS . | NEG . |
| Adverse genomic risk | 22 (96%) | 1 (4%) | 15 (68%) | 7 (32%) |
| Standard genomic risk | 14 (93%) | 1 (7%) | 7 (47%) | 8 (53%) |
| T-ALL | MRD at TP1 | MRD at TP2 | ||
| POS | NEG | POS | NEG | |
| Adverse genomic risk | 5 (100%) | 0 (0%) | 3 (50%) | 3 (50%) |
| Standard genomic risk | 3 (50%) | 3 (50%) | 0 (0%) | 6 (100%) |
| Combined | MRD at TP1 | MRD at TP2 | ||
| POS | NEG | POS | NEG | |
| Adverse genomic risk | 27 (96%) | 1 (4%) | 18 (64%) | 10 (36%) |
| Standard genomic risk | 17 (81%) | 4 (19%) | 7 (33%) | 14 (67%) |
| P = .0002 | P = .045 | |||
| B-ALL . | MRD at TP1 . | MRD at TP2 . | ||
|---|---|---|---|---|
| . | POS . | NEG . | POS . | NEG . |
| Adverse genomic risk | 22 (96%) | 1 (4%) | 15 (68%) | 7 (32%) |
| Standard genomic risk | 14 (93%) | 1 (7%) | 7 (47%) | 8 (53%) |
| T-ALL | MRD at TP1 | MRD at TP2 | ||
| POS | NEG | POS | NEG | |
| Adverse genomic risk | 5 (100%) | 0 (0%) | 3 (50%) | 3 (50%) |
| Standard genomic risk | 3 (50%) | 3 (50%) | 0 (0%) | 6 (100%) |
| Combined | MRD at TP1 | MRD at TP2 | ||
| POS | NEG | POS | NEG | |
| Adverse genomic risk | 27 (96%) | 1 (4%) | 18 (64%) | 10 (36%) |
| Standard genomic risk | 17 (81%) | 4 (19%) | 7 (33%) | 14 (67%) |
| P = .0002 | P = .045 | |||
NEG, MRD negative; POS, MRD positive.